Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
Lonial S, Nooka AK, Thulasi P, Badros AZ, Jeng BH, Callander NS, Potter HA, Sborov D, Zaugg BE, Popat R, Degli Esposti S, Byrne J, Opalinska J, Baron J, Piontek T, Gupta I, Dana R, Farooq AV, Colby K, Jakubowiak A. Lonial S, et al. Among authors: popat r. Blood Cancer J. 2021 May 26;11(5):103. doi: 10.1038/s41408-021-00494-4. Blood Cancer J. 2021. PMID: 34039952 Free PMC article. Clinical Trial.
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD Jr, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD. Trudel S, et al. Among authors: popat r. Lancet Oncol. 2018 Dec;19(12):1641-1653. doi: 10.1016/S1470-2045(18)30576-X. Epub 2018 Nov 12. Lancet Oncol. 2018. PMID: 30442502 Free PMC article. Clinical Trial.
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study.
Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Hoos A, Gupta I, Bragulat V, He Z, Opalinska JB, Cohen AD. Trudel S, et al. Among authors: popat r. Blood Cancer J. 2019 Mar 20;9(4):37. doi: 10.1038/s41408-019-0196-6. Blood Cancer J. 2019. PMID: 30894515 Free PMC article. Clinical Trial.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD. Lonial S, et al. Among authors: popat r. Lancet Oncol. 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16. Lancet Oncol. 2020. PMID: 31859245 Clinical Trial.
Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial.
Popat R, Warcel D, O'Nions J, Cowley A, Smith S, Tucker WR, Yong K, Esposti SD. Popat R, et al. Haematologica. 2020 May;105(5):e261-e263. doi: 10.3324/haematol.2019.235937. Epub 2020 Feb 27. Haematologica. 2020. PMID: 32107339 Free PMC article. No abstract available.
Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations.
Chavda SJ, Pocock R, Cheesman S, Lee KM, Dowling E, Marks DJB, Kyriakou C, Lee L, Sive J, Wechalekar A, Rabin N, Yong K, Popat R. Chavda SJ, et al. Among authors: popat r. Br J Haematol. 2020 Sep;190(5):e312-e316. doi: 10.1111/bjh.16889. Epub 2020 Jun 14. Br J Haematol. 2020. PMID: 32535901 Free article. No abstract available.
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, Jakubowiak A, Sborov D, Zaugg BE, Badros AZ, Jeng BH, Callander NS, Opalinska J, Baron J, Piontek T, Byrne J, Gupta I, Colby K. Farooq AV, et al. Among authors: popat r. Ophthalmol Ther. 2020 Dec;9(4):889-911. doi: 10.1007/s40123-020-00280-8. Epub 2020 Jul 25. Ophthalmol Ther. 2020. PMID: 32712806 Free PMC article.
Antibody-drug conjugates for multiple myeloma.
McMillan A, Warcel D, Popat R. McMillan A, et al. Among authors: popat r. Expert Opin Biol Ther. 2021 Jul;21(7):889-901. doi: 10.1080/14712598.2020.1802422. Epub 2020 Aug 12. Expert Opin Biol Ther. 2021. PMID: 32729730 Review.
213 results